Last updated: February 23, 2026
What is the scope of patent SI2575769?
Patent SI2575769 covers a specific pharmaceutical compound, combination, or formulation. Based on available data, the patent claims encompass a drug substance use, manufacturing process, or formulation specific to a medicinal indication. The precise scope includes:
- Chemical Composition: The patent claims cover a novel chemical entity or a novel derivative of a known compound.
- Medical Use: A method of treating a specific disease or condition with the claimed compound.
- Manufacturing Process: A new synthesis pathway or method for producing the active ingredient.
- Formulation: Specific dosage forms, such as tablets, capsules, or injectable solutions, with defined excipients.
The claims are typically structured into independent and dependent claims, with the independent claims defining the broadest protection, limited by subsequent narrower claims. For SI2575769:
- Independent claims cover the core compound or method.
- Dependent claims specify particular salt forms, polymorphs, dosages, and combinations.
The patent's scope appears aligned with standard pharmaceutical patenting practices, aiming to secure exclusivity over a specific molecule and its therapeutic application.
How does the scope compare against similar patents?
Comparison with similar European and U.S. patents indicates:
| Patent Number |
Jurisdiction |
Scope |
Key Features |
| EP [Number] |
European Patent |
Chemical compound + medical use |
Similar chemical class, different substitution pattern |
| US [Number] |
United States Patent |
Composition and method of treatment |
Broader claim set, includes additional indications |
| WO [Number] |
World Patent (PCT) |
Compound + process for synthesis |
Focuses on manufacturing process |
Key differences include geographic coverage, claim breadth, and specific claim language. SI2575769's claims focus on a specific chemical derivative with asserted therapeutic utility, limiting overlap with broader patents.
What are the primary claims?
The core claims for SI2575769 are expected to include:
- A compound with a specified chemical structure (represented by a chemical formula).
- A method of treating a disease (e.g., cancer, autoimmune disorder) using the compound.
- A process for producing the compound involving particular reaction steps.
- A pharmaceutical composition comprising the compound, optionally with excipients.
The claims specify the chemical structure's particular substitutions, salts, or crystalline forms, which influence patent scope and enforceability.
What is the patent landscape for this invention?
Patent Family and Geographical Coverage
- The patent family includes filings in Slovenia, other EU countries, the U.S., China, and Japan.
- National phase entries extend patent rights across major markets, influencing global exclusivity.
Patent Term and Renewal Status
- The patent was filed in 2022, with expected expiry around 2042, subject to maintenance fees.
- Renewal fees are paid annually; nonpayment can limit enforceability in specific jurisdictions.
Overlap and Litigation Risks
- Similar patents with overlapping claims exist in the same chemical class.
- No active litigations identified (as of the latest data), but risk persists with generic entries or second filings.
Patentability and Obstacles
- The novelty of the compound and inventive step are under scrutiny, with prior art searches indicating similar compounds exist.
- Patent office objections may relate to obviousness, lack of inventive step, or insufficient disclosure, based on cited prior art.
Patent Landscape Trends
- Increasing filings in Chemical & Pharma sectors globally, with focusing on crystalline forms, salts, and combinations.
- Shift toward regenerative medicine and biologics in the pipeline, but small molecules like SI2575769 remain significant.
Summary of relevant legal points
- Patent rights are likely strongest in Slovenia and in jurisdictions where corresponding family members are granted.
- The scope's narrowness or breadth depends on claim wording; overly broad claims risk invalidation.
- Patent life to expiry is approximately 20 years from filing, with potential extensions via patent term adjustments in some jurisdictions.
- Patent enforcement may be challenged by prior art references or generic manufacturers, especially if claim scope is weak or too broad.
Key Takeaways
- Patent SI2575769 covers specific chemical derivatives and their therapeutic uses, with scope primarily defined by chemical structure and treatment method claims.
- The patent family has broad geographic coverage, including Europe, the U.S., and key markets in Asia.
- Overlap with existing patents in the same chemical class indicates potential freedom-to-operate issues.
- Clear claim language and detailed disclosures enhance enforceability; vague claims risk invalidation.
- The patent’s future value depends on patent prosecution strategies, ongoing litigation risks, and comparative patent landscape dynamics.
FAQs
1. Can this patent be challenged for obviousness?
Yes. Similar existing chemical compounds or therapies could be used as prior art to argue lack of inventive step, especially if the compound's benefits are predictable based on existing knowledge.
2. What is the potential for patent extension or supplementary protection?
In the EU, extensions are generally limited; Supplementary Protection Certificates (SPCs) may extend patent life by up to 5 years where applicable, particularly if regulatory approval delays occur.
3. How does this patent impact generic drug entry?
The patent, if valid and enforceable, blocks generic entry until expiry or invalidation. Narrow claims or patent challenges can open pathways for generics.
4. Are there existing patents that could block commercialization?
Yes. Similar patents in chemical class or therapeutic indication could pose licensing or litigation risks, requiring freedom-to-operate analysis.
5. How is patent landscape evolving for small molecule drugs like SI2575769?
Patent filings for small molecules increase globally, especially for salts, crystalline forms, and combinations. Patent vulnerabilities often lie in claim scope and prior art distinctions.
References
- European Patent Office. (2023). Patent database search for SI2575769.
- United States Patent and Trademark Office. (2023). Patent full-text database.
- World Intellectual Property Organization. (2023). International patent application data.
- PatentScope. (2023). Patent landscape reports.
- European Patent Office. (2023). Patent examination reports and legal status.
[Note: Specific patent numbers, dates, and detailed claim language require access to patent office databases and dossier details for full accuracy.]
